Raymond James & Associates Madrigal Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 20,321 shares of MDGL stock, worth $4.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,321
Previous 20,284
0.18%
Holding current value
$4.31 Million
Previous $5.42 Million
5.11%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MDGL
# of Institutions
298Shares Held
22MCall Options Held
757KPut Options Held
370K-
Janus Henderson Group PLC London, X02.49MShares$528 Million0.38% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.06MShares$436 Million7.86% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$419 Million7.35% of portfolio
-
Rtw Investments, LP New York, NY1.92MShares$407 Million8.96% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.85MShares$393 Million39.74% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $3.63B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...